BridgeBio (BBIO) CEO Neil Kumar sells 26,103 shares in Rule 10b5-1 trades
Rhea-AI Filing Summary
BridgeBio Pharma, Inc. Chief Executive Officer and director Neil Kumar reported open-market sales of 26,103 shares of common stock on May 21, 2026. The shares were sold at weighted average prices within ranges from $66.81 to $70.97 per share under a pre-arranged Rule 10b5-1 sales plan adopted on March 31, 2025.
Following these transactions, Kumar directly holds 267,174 BridgeBio common shares. In addition, the Kumar Haldea Revocable Trust and the Kumar Haldea Family Irrevocable Trust, for which he serves as co-trustee, hold 4,358,447 and 555,686 shares, respectively, although he disclaims beneficial ownership of those trust-held shares except to the extent of any pecuniary interest.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 26,103 shares
Net Sell
7 txns
Insider
Kumar Neil
Role
Chief Executive Officer
Sold
26,103 shs ($1.81M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 2,256 | $67.5687 | $152K |
| Sale | Common Stock | 6,725 | $68.3025 | $459K |
| Sale | Common Stock | 5,072 | $69.2235 | $351K |
| Sale | Common Stock | 11,250 | $70.4814 | $793K |
| Sale | Common Stock | 800 | $70.9189 | $57K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 243,327 shares (Direct);
Common Stock — 555,686 shares (Indirect, By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.);
Common Stock — 4,358,447 shares (Indirect, By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.)
Footnotes (7)
- F1. This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025.
- F2. Represents the weighted average sale price of the shares sold from $66.81 to $67.80 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
- F3. Represents the weighted average sale price of the shares sold from $67.81 to $68.80 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
- F4. Represents the weighted average sale price of the shares sold from $68.81 to $69.78 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
- F5. Represents the weighted average sale price of the shares sold from $69.86 to $70.85 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
- F6. Represents the weighted average sale price of the shares sold from $70.86 to $70.97 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
- F7. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.
Key Figures
Shares sold: 26,103 shares
Sale price range (footnotes): $66.81–$70.97 per share
Direct holdings after sale: 267,174 shares
+2 more
5 metrics
Shares sold
26,103 shares
Total common shares sold on May 21, 2026
Sale price range (footnotes)
$66.81–$70.97 per share
Weighted average price ranges for reported sales
Direct holdings after sale
267,174 shares
Direct BridgeBio common stock owned following transactions
Revocable trust holdings
4,358,447 shares
Kumar Haldea Revocable Trust, with Neil Kumar as co-trustee
Family irrevocable trust holdings
555,686 shares
Kumar Haldea Family Irrevocable Trust, with Neil Kumar as co-trustee
Key Terms
Rule 10b5-1 sales plan, weighted average sale price, beneficial ownership, Section 16
4 terms
Rule 10b5-1 sales plan regulatory
"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."
weighted average sale price financial
"Represents the weighted average sale price of the shares sold from $66.81 to $67.80 per share."
beneficial ownership regulatory
"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Section 16 regulatory
"shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."
Section 16 is a U.S. securities law rule that governs the trading and disclosure obligations of company insiders — typically officers, directors and large shareholders — to promote transparency and deter unfair profit-taking. It requires insiders to publicly report their stock trades and allows companies or the issuer to reclaim quick, short-term profits from certain insider trades, like a scoreboard and a refund policy that help investors see and limit possible insider advantage.
AI-generated analysis. How Rhea-AI works. Not financial advice.
